Jazz Pharmaceuticals to Showcase Key Oncology Data at SABCS and ASH 2024

Jazz Pharmaceuticals plc  will deliver a total of 15 abstracts outlining its oncology pipeline at two of the leading industry conferences this December. At the 2024 SABCS planned for the 10th–13th of December in San Antonio, the company aims at presenting a trial-in-progress poster of the EmpowHER-303 Phase 3 trial. This trial compares zanidatamab-hrii (Ziihera®) with trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who had progressed after trastuzumab deruxtecan treatment. Also, a poster spotlight will present Phase 1b/2 data of the combination of zanidatamab with evorpacept in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer.

These presentations come after Ziihera® received FDA approval to be administered in cases of HER2-positive biliary tract cancer that has been previously treated, unresectable, or has metastasised, which is a milestone for Jazz Pharmaceuticals. ’We are looking forward to unveiling more efficacy and safety data on zanidatamab for HER2-expressing cancer,’ said Jazz Pharmaceuticals’ EVP and global head of R&D, Rob Iannone, MD, MScCE. The biliary tract cancer and gastro-oesophageal adenocarcinoma first-line are various Phase 3 trials with progression-free survival in Q2 2025.

Cross-sectional to this development, Jazz Pharmaceuticals will also be exhibiting 13 abstracts on the 66th Annual ASH Meeting between December 7-10, the event bringing together researchers, physicians, allied health labours, and others interested in haematologic cancer and blood sorders. These presentations are in line with the continued efforts of the company to develop therapies for hard-to-manage cancers and enhance the quality of life of patients with related haematologic diseases.